PARIS (dpa-AFX) - Acorda Therapeutics Inc. (ACOR) has decided to discontinue
the development of Dalfampridine for treatment of post-stroke walking
difficulties, following disappointing results from its trial, dubbed MILESTONE.
Although the study...
NEW YORK CITY (dpa-AFX) - Amarin Corp. plc (AMRN) has completed
randomization of patients in its phase III cardiovascular outcomes study to
determine whether Vascepa will reduce cardiovascular risk in statin treated
patients that still have...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.